Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult4. fázis

Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP

A legfontosabb adatok

Ki végzi
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
4. fázis
Résztvevők
150 fő, tervezett
Kezdés
2025. dec. 1.
Várható befejezés
2027. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Eltrombopag
  • Placebo
A regiszteradat frissítve
2025. szeptember 24.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people aged 12 to 75 with severe primary immune thrombocytopenia (ITP), a condition with very low platelets. Everyone gets high-dose dexamethasone plus rhTPO in hospital. People who respond then get eltrombopag or placebo for 10 weeks.

Életkor
12 to 75 years
Nem
All sexes
A betegség stádiuma
Primary ITP confirmed by bone marrow biopsy within 3 months. Platelet count below 20×10⁹/L within 48 hours before the study drug. ECOG performance status 0-1, meaning fully active or only mildly limited.
Korábbi kezelés
Earlier rescue treatments (such as platelet transfusion, IVIG, cyclophosphamide) must have ended at least 2 weeks before. TPO-RAs or corticosteroids must be stopped at least 14 days before. Maintenance immune-suppressing drugs must be at a stable dose for at least 1 month. Anti-CD20 antibodies stopped at least 6 months before. Spleen removal at least 6 months before.
Biomarker vagy leletérték
Absolute neutrophil count ≥1.5×10⁹/L. Total bilirubin ≤1.5×ULN; ALT, AST, ALP ≤3×ULN; creatinine ≤1.5×ULN and creatinine clearance ≥50 mL/min. Normal blood clotting tests. Negative pregnancy test for women who can become pregnant.

A részvétel fő kizáró okai

  • ITP that did not respond to TPO-RAs, anti-CD20 therapy or spleen removal
  • Pregnant or breastfeeding women
  • ITP caused by another disease or by drugs, or other diseases causing low platelets
  • Past brain bleeding or severe organ bleeding, or recent blood clots or serious heart disease
  • HIV, hepatitis B or hepatitis C infection, now or in the past

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Age between 12 and 75 years, regardless of gender
  • ECOG performance status of 0-1
  • Diagnosis of primary ITP confirmed by bone marrow biopsy (valid within 3 months) and other relevant assessments; baseline platelet count (PLT) <20×10⁹/L within 48 hours prior to administration of study medication
  • Adequate function of major organs as defined below (based on the clinical laboratory reference ranges of the study center):
  • Hematology: Absolute neutrophil count (ANC) ≥1.5×10⁹/L; no abnormalities unrelated to ITP, except a) PLT <20×10⁹/L at Day 1 or within 48 hours of Day 1 is allowed; b) Hemoglobin: If anemia is clearly due to ITP-related bleeding, hemoglobin lower than the lower limit of normal (LLN) may be permitted at investigator's discretion
  • Biochemistry: Total bilirubin (TBIL) ≤1.5×ULN; ALT, AST, ALP ≤3×ULN; serum creatinine ≤1.5×ULN and creatinine clearance ≥50 mL/min
  • Coagulation: Prothrombin time (PT) within ±3 seconds of normal range; activated partial thromboplastin time (APTT) ≤1.5×ULN unless on medications known to alter INR/APTT; no known history of coagulopathy other than ITP
  • Prior ITP rescue treatments (e.g., platelet transfusion, IVIG, immunomodulators, cyclophosphamide) must have ended or failed at least 2 weeks prior to enrollment (except corticosteroids); TPO-RAs or corticosteroids must be discontinued ≥14 days before study start
  • Patients on maintenance immunosuppressive therapy (e.g., corticosteroids, azathioprine, danazol, cyclosporine A, mycophenolate mofetil, or traditional Chinese platelet-raising medicine) must be on stable doses for at least 1 month prior to enrollment. Patients previously treated with anti-CD20 antibodies must have discontinued at least 6 months prior; splenectomy patients may enroll ≥6 months post-surgery
  • Female subjects of childbearing potential must have a negative serum pregnancy test within 24 hours prior to first dosing; all subjects agree to use effective contraception during the study and for 6 months after its completion
  • No known contraindications to corticosteroids, rhTPO, or eltrombopag and willing to undergo rhTPO followed by eltrombopag treatment
  • Willingness to participate and ability to provide written informed consent. For participants aged ≥12 years, both the subject and their legal guardian must sign the informed consent form

Ki nem vehet részt

  • History of intracranial hemorrhage or severe bleeding (>CTCAE Grade 3) of vital organs; symptomatic gastrointestinal bleeding (e.g., hematemesis, melena) within 6 months prior to screening (asymptomatic occult blood and hemorrhoids excluded)
  • History of any arterial or venous thrombosis (e.g., stroke, TIA, MI, DVT, PE) within 6 months prior to enrollment and at least two of the following risk factors: hormone replacement therapy, oral contraceptives (including estrogens), smoking, diabetes, hypercholesterolemia, pharmacologically controlled hypertension, hereditary thrombophilia
  • Severe cardiovascular disease within 6 months prior to enrollment (e.g., NYHA Class III-IV), arrhythmias increasing thrombotic risk (e.g., atrial fibrillation), or history of coronary stenting, angioplasty, or bypass surgery
  • Concurrent serious or life-threatening malignancy
  • Use of any herbal medicine or nutritional supplement within 1 week prior to study start, except for vitamins and minerals
  • Refractory ITP (failure to respond to first- and second-line TPO-RAs, anti-CD20 therapy, or splenectomy)
  • Evidence of secondary ITP (e.g., untreated Helicobacter pylori, leukemia, lymphoma, autoimmune diseases such as SLE, Hashimoto's thyroiditis), drug-induced thrombocytopenia (e.g., due to anticonvulsants, antibiotics, heparin), or multi-lineage autoimmune cytopenias (e.g., Evans syndrome)
  • History or presence of any primary disease other than ITP that may cause thrombocytopenia (e.g., myelodysplastic syndrome, congenital bone marrow failure syndromes such as Fanconi anemia or dyskeratosis congenita, aplastic anemia), as judged by the investigator
  • Ongoing or uncontrolled serious infections (≥CTCAE Grade 2)
  • Any condition deemed by the investigator to make the subject unsuitable for participation, including but not limited to medical, social, or psychological factors affecting safety or study compliance
  • Use of drugs that significantly affect platelet function (e.g., aspirin, clopidogrel, NSAIDs) or anticoagulants for >3 days within 2 weeks before and during the study
  • Laboratory or clinical evidence of HIV infection, active hepatitis C, active hepatitis B, or previous history of these infections. Patients with positive HBsAg are excluded. Those with HBsAg-negative but HBcAb-positive must undergo HBV DNA testing; if positive, they are excluded
  • Pregnant or lactating women

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 12 és 75 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To address the clinical need for improving early response rates, maintaining sustained responses, reducing relapse rates, and minimizing adverse events in the treatment of immune thrombocytopenia (ITP), the investigators developed a comprehensive in-hospital and post-discharge management strategy. In this study, hospitalized participants will receive a 14-day regimen of high-dose dexamethasone (HD-DXM) plus recombinant human thrombopoietin (rhTPO), followed by a 10-week course of oral eltrombopag olamine dry suspension after discharge. The investigators aim to evaluate the efficacy and safety of this sequential treatment strategy in adult ITP patients.

A vizsgálat 2 csoportja

  • Eltrombopag GroupA vizsgált kezelés

    Participants who achieve a complete response (CR) or response (R) after HD-DXM combined with rhTPO treatment will be randomized in a 2:1 ratio into the eltrombopag group or the placebo group. Observation group: Participants will receive eltrombopag for oral suspension (EPAG-pfos) for ten weeks.

    Kezelés: Eltrombopag

  • Placebo groupMár használt kezelés, összehasonlításként

    Participants who achieve a complete response (CR) or response (R) after HD-DXM combined with rhTPO treatment will be randomized in a 2:1 ratio into the eltrombopag group or the placebo group. Control group: Participants did not receive sequential EPAG-pfos treatment.

    Kezelés: Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Efficacy and Safety of Glucocorticoids Combined With Recombinant Human Thrombopoietin (rhTPO) Sequential Eltrombopag Olamine for Severe Primary Immune Thrombocytopenia (ITP) in Adults
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07189910: ki vehet részt
A regiszteradat frissítve
2025. szeptember 24.